Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Year3000on Oct 04, 2022 4:59pm
78 Views
Post# 35005200

RE:RE:RE:RE:RE:Special Meeting Content

RE:RE:RE:RE:RE:Special Meeting Content

Of course, it all makes sense now... mainpointe who are paying for the dermal injector to get to market have been delaying so that Andrew can buy his shares before it's release.

Andrew is getting in before releasing the arbitration results so that Andrew can get his cheap shares.

no wonder why they haven't released anything. 


on the flip side, I think without Andrew the company would have gone under a long time ago... so for me he can have the cheap shares. as long as the injector is launched shortly afterwards as well as the arbitration results I'm happy. 

what I'm unhappy about is being in the dark for so long, so if this happens I hope it will bring an end to all that. GLTA

<< Previous
Bullboard Posts
Next >>